SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-24-028548
Filing Date
2024-02-08
Accepted
2024-02-08 17:44:27
Documents
1
Group Members
VERSANT VANTAGE I GP, L.P.VERSANT VANTAGE I GP-GP, LLCVERSANT VANTAGE I, L.P.VERSANT VENTURES VI GP, L.P.VERSANT VENTURES VI GP-GP, LLC

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d754244dsc13da.htm SC 13D/A 116203
  Complete submission text file 0001193125-24-028548.txt   118037
Mailing Address ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104
Business Address ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 (415) 801-8100
Versant Venture Capital VI, L.P. (Filed by) CIK: 0001687880 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Subject) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91770 | Film No.: 24610427
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)